TRIM21 and Fatigable weakness: As shown in a recent study on MDA5 subgroup analysis, a higher proportion of patients with high-titer anti-MDA5 was found in the subgroup with high mortality, and myasthenia, rash, arthritis and anti-Ro52 were also most prevalent in the subgroup with high mortality (24).